1356840-03-3
Chemical Structure
Temocapril-d5
- CAS No.: 1356840-03-3
- Formula:C23H23D5N2O5S2
- Molecular Weight:481.64
IUPAC Name: 2-((2S,6R)-6-(((S)-1-ethoxy-1-oxo-4-(phenyl-d5)butan-2-yl)amino)-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl)acetic acid
InChIKey: FIQOFIRCTOWDOW-RJJPJTEUSA-N
SMILES: C(C(O)=O)N1C[C@](SC[C@H](N[C@@H](CCC2=C(C(=C(C(=C2[2H])[2H])[2H])[2H])[2H])C(OCC)=O)C1=O)(C3=CC=CS3)[H]
Biological Activity: Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Temocapril-d5 | Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Temocapril (Standard) | ≥98% | Temocapril (Standard) is the analytical standard of Temocapril. This product is intended for research and analytical applications. Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Temocapril | 98.14% | Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Keisuke Ohnishi, et al. Angiotensin-Converting Enzyme Inhibitor Does Not Suppress Renal Angiotensin II Levels in Angiotensin I–Infused Rats. J Pharmacol Sci. 2013; 122(2): 103–108. [Content Brief]
